References Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S
doi: 10.1136/BMJOPEN-2020-038856
Histopathological examination was carried out by a blind reading of the histology
Third, in neurodegenerative diseases, inhibited autophagy typically leads to an accumulation of pathological proteins, ultimately resulting in the aggregation of LAMP1 and increase in its levels 30,31
Still, side effects can occur, especially during the adjustment period
Coding Best Practices for GLP-1 Claims Always verify payer coverage policies Confirm FDA-approved indication Use the most specific ICD-10 code Include BMI codes when required Ensure documentation supports medical necessity Confirm whether the drug is pharmacy or medical benefit Avoid unclassified J-codes unless required Track prior authorization approvals Document patient counseling and monitoring Watch for Medicare weight-loss exclusions Denial Prevention Checklist Before submitting GLP-1-related claims, confirm: Correct diagnosis code selection BMI documented and coded PA approval on file Proper benefit type (pharmacy vs medical) E/M level supported by documentation Drug coverage confirmed by payer GLP-1 medications are transforming diabetes and obesity care, but they bring complex billing and compliance challenges
